Desreux J, Gaspard U, Bleret V, et al. - Le cancer du sein en Belgique: pourquoi sommes-nous les premiers en Europe? Rev Med Liege, 2011, 66, 231-237.
Cardoso F, Costa A, Norton L, et al. - 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast, 2012, 21, 242-252.
Cardoso F, Harbeck N, Fallowfield L, et al. - Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2012, 23 Suppl 7, vii11-vii19.
http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf, NCCN Clinical Practice Guidelines: Breast Cancer v3, 2014, consulté le 17/5/2014
Chia S, Gradishar W, Mauriac L, et al. - Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol, 2008, 26, 1664-1670.
Johnston SR, Kilburn LS, Ellis P, et al. - Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptorpositive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol, 2013, 14, 989-998.
Osborne CK, Wakeling A, Nicholson RI. - Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer, 2004, 90 Suppl 1, S2-S6.
Gennigens C, Sautois B, Jerusalem G. - Evérolimus (RAD001/Afinitor®) dans le traitement du cancer du rein métastatique. Rev Med Liege, 2010, 65, 212-216.
Yao JC, Shah MH, Ito T, et al. - Everolimus for advanced pancreatic neuroendocrine tumors. New England J Med, 2011, 364, 514-523.
Arrêté Ministériel du 16/7/2013. Moniteur belge du 19/7/13, 2013, 45449-45480.
Yamnik RL, Digilova A, Davis DC, et al. - S6 kinase I regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem, 2009, 284, 6361-6369.
Ellard SL, Clemons M, Gelmon KA, et al. - Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol, 2009, 27, 4536-4541.
Baselga J, Semiglazov V, Van Dam P, et al. - Phase II randomized study of neoadjuvant évérolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol, 2009, 27, 2630-2637.
Bachelot T, Bourgier C, Cropet C, et al. - Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol, 2012, 30, 2718-2724.
Baselga J, Campone M, Piccart M, et al. - Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med, 2012, 366, 520-529.
Yardley DA, Noguchi S, Pritchard KI, et al. - Everolimus Plus Exemestane in Postmenopausal Patients with HR (+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Adv Ther, 2013, 30, 870-884.
Campone M, Bachelot T, Gnant M, et al. - Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer, 2013, 49, 2621-2632.
Pritchard KI, Burris HA, III, Ito Y, et al - Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer, 2013, 13, 421-432.
Piccart M, Hortobagyi GN, Campone M, et al. - Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2. Eur J Cancer, 2014, 50, Suppl 3, S1.
Treilleux I, Arnedos M, Cropet C, et al. - Predictive markers of everolimus efficacy in hormone receptor positive (HR+) metastatic breast cancer (MBC): final results of the TAMRAD trial translational study. J Clin Oncol, 2013, 31, Suppl 15, abst 510.
Hortobagyi GN, Piccart-Gebhart MJ, Rugo HS, et al. - Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2. J Clin Oncol, 2013, 31, Suppl 15, abst LBA509.
Burris HA, III, Lebrun F, Rugo HS, et al. - Healthrelated quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer, 2013, 119, 1908-1915.
Aapro M, Andre F, Blackwell K, et al. - Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol, 2014, 25, 763-773.
http://clinicaltrials.gov/ct2/show/NCT01805271?term=NCT01805271&rank=1 Consulté le 13/05/2014.
http://clinicaltrials.gov/ct2/show/NCT01674140?term=NCT01674140&rank=1 Consulté le 13/05/2014.
http://clinicaltrials.gov/ct2/show/NCT01698918?term=NCT01698918&rank=1 Consulté le 13/05/2014.
http://clinicaltrials.gov/ct2/show/NCT01633060?term=NCT01633060&rank=1 Consulté le 13/05/2014.
Van Cutsem E, Tabernero J, Lakomy R, et al. - Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol, 2012, 30, 3499-3506.
Morrow PK, Wulf GM, Ensor J, et al. - Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol, 2011, 29, 3126-3132.
Andre F, Campone M, O'Regan R, et al. - Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol, 2010, 28, 5110-5115.
Hurvitz SA, Dalenc F, Campone M, et al. - A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat, 2013, 141, 437-446.
Jerusalem G, Fasolo A, Dieras V, et al. - Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat, 2011, 125, 447-455.
Andre F, O'Regan R, Ozguroglu M, et al. - Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol, 2014, 15, 580-591.
Jerusalem G, Andre F, Chen D, et al. - Evaluation of everolimus (EVE) in HER2+ advanced breast cancer (BC) with activated PI3K/mTOR pathway: exploratory biomarker observations from the BOLERO-3 trial. Eur J Cancer, 2013, 49, PS8.
http://clinicaltrials.gov/ct2/show/NCT00876395?term=NCT00876395&rank=1 Consulté le 13/05/2014.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.